Biocon Limited Stock Price Today (NSE: BIOCON)
Fundamental Score
Biocon Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Biocon Limited share price today is ₹417.20, down 0.07% on NSE/BSE as of 25 August 2026. Biocon Limited (BIOCON) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹70.83K (Cr). The 52-week high for BIOCON share price is ₹447.15 and the 52-week low is ₹337.05. At a P/E ratio of 143.00x, BIOCON is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 1.39% and a debt-to-equity ratio of 0.44.
Biocon Limited Share Price Chart — NSE/BSE Historical Performance
Biocon Limited share price chart: -4.35% return over the past month. 52-week high ₹447.15, 52-week low ₹337.05.
Biocon Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹410.90 | ₹417.20 | ₹407.00 | ₹417.20 | 30.87L (Cr) | |
| ₹413.50 | ₹421.60 | ₹412.20 | ₹417.50 | 26.91L (Cr) | |
| ₹418.00 | ₹420.80 | ₹413.15 | ₹417.00 | 39.93L (Cr) | |
| ₹424.10 | ₹425.30 | ₹416.20 | ₹420.00 | 46.28L (Cr) | |
| ₹427.75 | ₹430.50 | ₹422.60 | ₹427.40 | 37.90L (Cr) | |
| ₹424.10 | ₹426.00 | ₹420.30 | ₹426.00 | 19.60L (Cr) | |
| ₹426.00 | ₹429.90 | ₹423.00 | ₹426.10 | 22.89L (Cr) | |
| ₹430.00 | ₹436.20 | ₹425.30 | ₹426.35 | 52.65L (Cr) | |
| ₹428.00 | ₹442.50 | ₹421.25 | ₹436.60 | 109.28L (Cr) | |
| ₹426.00 | ₹428.65 | ₹422.30 | ₹425.20 | 32.96L (Cr) |
Biocon Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹429.00 | ₹442.50 | ₹407.00 | ₹417.20 | -2.75% | |
| ₹420.95 | ₹447.15 | ₹394.85 | ₹425.70 | +1.13% | |
| ₹431.20 | ₹435.00 | ₹405.31 | ₹417.80 | -3.11% | |
| ₹359.20 | ₹440.40 | ₹359.20 | ₹428.65 | +19.33% | |
| ₹369.00 | ₹371.90 | ₹337.70 | ₹359.65 | -2.53% | |
| ₹380.00 | ₹402.80 | ₹357.30 | ₹360.90 | -5.03% | |
| ₹369.90 | ₹401.05 | ₹360.55 | ₹389.80 | +5.38% | |
| ₹393.00 | ₹398.95 | ₹359.05 | ₹366.80 | -6.67% | |
| ₹398.35 | ₹412.50 | ₹375.55 | ₹393.90 | -1.12% | |
| ₹372.10 | ₹424.95 | ₹372.00 | ₹398.35 | +7.05% | |
| ₹341.00 | ₹380.35 | ₹341.00 | ₹372.10 | +9.12% | |
| ₹349.00 | ₹373.85 | ₹337.05 | ₹341.00 | -2.29% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Biocon's biosimilar and insulin strategies offer upside, but high valuation and debt warrant caution.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Biocon launched Bosaya™ and Aukelso™ (denosumab biosimilars) in the US. These biosimilars, approved by the FDA in September 2025, target osteoporosis and bone metastasis, conditions that affected an estimated 10 million and 330,000 adults respectively in 2024. Biocon is also positioning itself as a major global insulin player as competitors shift focus to GLP-1 therapies.
CORE STORY (THE REAL GAME)
Biocon is executing a biosimilar play, leveraging its portfolio and manufacturing capabilities to capture market share in key therapeutic areas like oncology, immunology, and diabetes. The focus is on affordability and accessibility, particularly in the US and emerging markets.
- US launch of denosumab biosimilars targets a $5B market
- Strategic focus on insulin as competitors shift to GLP-1
- Q3FY26 Net Profit up 475%
- Successful penetration of the US biosimilar market
- Higher insulin margins than GLP-1
- New biosimilar approvals and launches
- High P/E of 111.2x vs industry P/E of 31.77x
- Low Interest Coverage of 1.9x
- Debt/Equity ratio of 0.62
FII increased stake by 0.57%, while DII decreased stake by 0.77%
Indian pharma sector projected to reach $130 billion by 2030, driven by global demand and innovation.
Free Cash Flow 5Y: ₹1570.0 Cr - Yes
Biocon's 3-6 month outlook hinges on successful US biosimilar launches and capitalizing on the insulin market shift. Watch for regulatory approvals and market penetration data.
Primary Thesis Risk
Slower than expected biosimilar adoption in the US will crush the narrative.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Biocon Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biocon Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOCON across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (23.05%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (349.36%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (18.96% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Cash Generation (₹2314.30 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.45%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 31.47%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (1.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.06%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 143.00x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-14.69% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-12.23% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.45x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Biocon Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Biocon Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Biocon LimitedBiocon Limited...Selected✓ BIOCON • 532523 | 30.2/100 | ₹417.20₹417 | ₹70826.50₹70826.50 | 143.00Average 143.0 Average | 1.39%Poor 1.39% Poor | 3.06%Poor 3.06% Poor | 0.44Excellent 0.4 Excellent | -12.23%Poor -12.23% Poor | 18.96%Excellent 18.96% Excellent | 0.12% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1875.10₹1875 | ₹468821.49₹468821.49 | 38.76Average 38.8 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹8588.00₹8588 | ₹193163.97₹193163.97 | 66.04Average 66.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4971.00₹4971 | ₹169902.02₹169902.02 | 77.90Average 77.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1431.10₹1431 | ₹116131.81₹116131.81 | 34.45Average 34.5 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1115.60₹1116 | ₹115375.77₹115375.77 | 25.57Average 25.6 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2232.00₹2232 | ₹113976.53₹113976.53 | 20.62Average 20.6 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2380.00₹2380 | ₹105053.91₹105053.91 | 51.28Average 51.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | — — | — — | 0.04% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1178.80₹1179 | ₹102660.46₹102660.46 | 31.86Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1645.00₹1645 | ₹90035.87₹90035.87 | 24.25Average 24.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1814.00₹1814 | ₹84016.75₹84016.75 | 76.84Average 76.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | — — | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price468821.49 Cr
- Divi's Laboratories Limited share price193163.97 Cr
- Torrent Pharmaceuticals Limited share price169902.02 Cr
- Cipla Limited share price116131.81 Cr
- Zydus Lifesciences Limited share price115375.77 Cr
Biocon Limited PE Ratio History
Historical price-to-earnings ratio for BIOCON — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.46 | ₹393.90 | 46.6x |
| FY 2024 | ₹8.54 | ₹365.35 | 42.8x |
| FY 2023 | ₹3.87 | ₹249.65 | 64.5x |
| FY 2022 | ₹5.42 | ₹261.85 | 48.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Biocon Limited Dividend History
Annual cash dividends paid by BIOCON — dividend yield 0.12%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹82.90 Cr |
| FY 2024 | ₹203.00 Cr |
| FY 2023 | ₹71.80 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Biocon Limited Quarterly Performance
Latest quarterly metrics for BIOCON — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
10.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
349.36%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
18.96%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-12.23%
Compounded annual net profit growth over 5 years
Biocon Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BIOCON — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Biocon Limited Financial Statements
Annual income statement, balance sheet and cash flow for Biocon Limited (BIOCON) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Biocon Limited
About BIOCON (Biocon Limited)
Biocon Ltd is a global biopharmaceutical innovator, deeply rooted in the Indian subcontinent yet reaching across continents with its diverse portfolio of life-saving medicines. The... company navigates the complex landscape of modern healthcare, pushing boundaries in research and development while striving to make treatments more accessible and affordable. From its state-of-the-art manufacturing facilities, Biocon formulates, produces, and distributes advanced therapies designed to combat a range of chronic and debilitating illnesses. With a keen focus on cutting-edge science and ethical practices, Biocon aspires to improve patient outcomes worldwide, contributing to a healthier future for all. Biocon's impact extends beyond simply manufacturing pharmaceuticals; it's about shaping the future of healthcare through pioneering biosimilar development and innovative solutions. At the core of Biocon's operations lies a commitment to tackling some of the most pressing health challenges facing the global population. This drive has led to the creation of a robust pipeline of generic formulations and active pharmaceutical ingredients (APIs), targeting critical therapeutic areas. These include cardiovascular diseases, diabetes, obesity, multiple sclerosis, and a range of cancers. Biocon's scientific teams work relentlessly to develop and refine these medicines, ensuring both efficacy and affordability. The company's unwavering dedication to innovation, paired with a robust global distribution network, enables Biocon to make a meaningful difference in the lives of countless patients around the world. Through strategic partnerships and a patient-centric approach, Biocon continues to address unmet medical needs and democratize access to essential medicines. Beyond generics and APIs, Biocon has emerged as a frontrunner in the development and commercialization of biosimilars. These biologics, offering similar efficacy and safety profiles to their reference counterparts, promise to revolutionize treatment options and provide cost-effective alternatives for patients. Biocon's biosimilar portfolio includes treatments for diabetes and oncology, reflecting the company's strategic focus on high-impact therapeutic areas. By leveraging its expertise in complex protein engineering and biomanufacturing, Biocon aims to lower the financial burden of biologic therapies, improving access for patients worldwide. With a strong emphasis on regulatory compliance and quality standards, Biocon is committed to establishing biosimilars as a cornerstone of accessible and sustainable healthcare.
Company Details
Key Leadership
Corporate Events
BIOCON Share Price: Frequently Asked Questions
What is the current share price of Biocon Limited?
Biocon Limited (BIOCON) trades at ₹417.20 on NSE and BSE. Market cap ₹70.83K (Cr). Educational data only.
What is the P/E ratio of Biocon Limited?
Biocon Limited has a P/E of 143.00x vs industry average 34.89x.
What is the Bull Run score for Biocon Limited?
Biocon Limited has a Bull Run score of 30.2/100 based on 25+ financial parameters.
Does Biocon Limited pay dividends?
Biocon Limited has a dividend yield of 0.12%. Past dividends don't guarantee future payments.
What is the ROE of Biocon Limited?
Biocon Limited has ROE of 1.39%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Biocon Limited?
Biocon Limited has debt-to-equity of 0.44.
Is Biocon Limited a good investment?
Bull Run gives Biocon Limited a score of 30.2/100. This is not investment advice — consult a SEBI-registered advisor.